Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Down 60.3% in June

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 597 shares, a decrease of 60.3% from the June 15th total of 1,503 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 3,169 shares, the short-interest ratio is currently 0.2 days.

Santen Pharmaceutical Price Performance

SNPHY opened at $13.12 on Wednesday. Santen Pharmaceutical has a 1-year low of $9.22 and a 1-year high of $13.93. The company has a 50 day simple moving average of $12.23 and a two-hundred day simple moving average of $11.41. The firm has a market cap of $4.23 billion and a P/E ratio of 0.10.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.